IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 1, January 2023
Impact Factor: 6.252

Quality Control and Quality Assurance in Pharmaceuticals

S. D. Sonawane, S. K. Bais, S. A. More
Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India

Abstract: *The international methods for evaluating the presence of geotaxis impurities (residual solvents and different inorganic and organic impurities) in pharmaceuticals are briefly discussed in this study. Due to national and international requirements, it is now important to give not only the purity profile but also the impurity profile of a certain pharmaceutical product. These factors, as well as the importance of the quality, effectiveness, and safety of medicines, are examined. These include the origin, types, and regulation of impurities. One of the requirements for the delivery of any nation's healthcare system has been defined as the availability of important medicines of high quality. This is because consumers can be harmed or even killed by subpar medications. Even in very small doses, the presence of undesirable compounds in a certain medicine may affect both its efficacy and safety. A pharmaceutical is a dynamic product that, unlike products from other industries, can alter between manufacture and final consumption in terms of colour, consistency, weight, and even chemical identity.*

Keywords: Quality Control

I. INTRODUCTION

Pharmaceutical development strives to produce a high-quality product and its manufacturing process to consistently deliver the product's targeted performance. The knowledge and experience gained from pharmaceutical development research and manufacturing experience are used to support the establishment of the design space, specifications, and manufacturing controls. Data from pharmaceutical development studies might be a helpful starting point for risk management. It is critical to realise that products cannot be evaluated for quality; rather, quality should be taken into account during the design process.

Modifications to formulation and production procedures throughout Development and lifecycle management should be seen as learning experiences that aid in the creation of the design space. Similar to this, it can be beneficial to include pertinent information learned from experiments that produced unexpected results. The applicant provides a design space proposal, which is evaluated and approved by the regulatory body. Working in the design space is not seen as a transition. A post-approval regulatory change process typically begins when a person leaves the design area because it is viewed as a change.

The product should always be created with the patient's needs and intended use in mind. Product development methods differ from firm to company and from one product to another. The strategy can also change, and it needs to be described in the submission. A candidate may opt for a blend of both an empirical and more methodical approach to development. Incorporating prior knowledge, experiment design study findings, A more deliberate approach to creation is demonstrated through quality risk management and knowledge management (ICH Q10) throughout the product's existence (also known as quality by design).

These systematic methods enhance the quality of the final product and help the regulator understand a company's strategy. The knowledge gained during the product life cycle can be updated to better understand products and processes.

1.1 Benefits of QBD

- QbD is a profitable venture.
- Get rid of batch errors.
- Reduce costly investigations and deviations.
- Prevent issues with regulatory compliance.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 1, January 2023
Impact Factor: 6.252

- Investing in organisational learning is doing so for the future.
- Science-wise, QbD is sound.
- Improved development choices.
- Giving technical workers more power.

1.2 Steps Involved in Quality by Design Products

1. Development of a novel molecular entity, preclinical, nonclinical, clinical, scale-up, and market approval submission
2. Real-time quality control, manufacturing, design space, and process analytical technology
3. Risk-based decision-making, control plan, ongoing product improvement, and product performance

1.3 Use of the Quality by Design principle (QbD)

A rigorous, methodical approach to the design and production of pharmaceuticals is known as quality by design (QbD).QbD can be used to advance pharmaceutical development and manufacturing compared to traditional methods.

1.4 Pharmaceutical Aspects: Traditional versus QbD.

Aspects	Traditional	QbD
Pharmaceutical Growth	Empirical	Reactive time issue and need for oos post approval change
Manufacturing Process	Fixed	Adaptable potential for innovation within the design space
Process Control	Process testing for broad or slow reaction when going online or offline	PAT is used for real-time feedback and feed forth.
Product Specification	Using batch dada as the primary quality control method	depending on the targeted product performance, a component of the overall control strategy
Control Strategy	mostly through testing of intermediate and final products	Real-time, risk-based, regulated, and shifted upstream release
Lifecycle Management	Reactive time issue and need for oos post approval change	Enabling continuous improvement within the design space

II. AUDIT

The phrase "Quality by Design" (QbD) refers to a thorough approach to drug development. Quality by design is a crucial aspect of the modern approach to pharmaceutical quality.

Regarding the proper component and vocabulary of quality by design, pharmaceutical scientists in the generic drug sector are largely in disagreement. This essay will cover pharmaceutical Quality by Design (QbD) and show how it may be applied to guarantee the quality of pharmaceuticals. A systemic strategy for pharmaceutical development is the QbD. It entails creating formulas and manufacturing procedures to guarantee a set level of product quality.

Examples of QbD components include defining the quality target product profile, identifying critical quality attributes, connecting the characteristics of the excipients in medicine, establishing design space, control strategy, and product life cycle management. Through the use of QbD, production and formulation variables are understood and under control to ensure pharmaceutical quality.

2.1 Objectives

- The achievement of quality products is QBD's primary goal.
- To obtain favourable performance testing results.
- Ensures that information acquired throughout development is combined with the products and processes.
- Pharmaceutical Quality by Design (QbD) is a methodical approach to development that begins with the goals

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 1, January 2023
Impact Factor: 6.252

that have been set and ends with the understanding of how things are done and the control of those things, all of which are based on trustworthy science and excellent risk management. Pharmaceutical Quality by Design may have the following objectives:

- the attainment of clinically-based relevant product quality requirements.
- To enhance process capability, decrease product variability, and raise product quality through improving product and process design, knowledge, and control.
- To enhance pharmaceutical manufacturing and product development procedures.
- To enhance root cause analysis and post-approval change management

2.2 Responsibilities of QbD:

Medical catastrophes like the Devonport incident of 1972 in Liverpool, United Kingdom, in which numerous patients died as a result of receiving dextrose infusions that had not been adequately sterilised, prompted the USFDA to provide its first advice on Process Validation in 1987. The 1987 document Guideline on General Principles of Process Validation was replaced by the FDA's revised advice for industry-process validation: general principles and practises, which was published in January 2011. The updated guideline reflects changes in process validation criteria as well as new concepts and principles. A more integrated approach to process validation and across the product lifecycle is made possible by the new methodology.

Additionally, it offers chances for automating the gathering, handling, and reporting of the necessary data.They are not laws, like other regulations, but following them provide a solid foundation for creating a compliance programme and producing high-quality pharmaceuticals

2.3 Planning Process

JM Juran, a pioneer in quality who has worked with countless organisations and thousands of managers, offers a fresh, utterly thorough method for structuring, defining and achieving high standards. He offers a practical method for companies to achieve strategic, market-driven objectives by following a structural approach to planning quality by using three case scenarios that cover the three primary economic sectors—service, manufacturing, and support. According to Juran, success in business now depends on quality. He lists waste, product failure, and market share loss as effects of subpar planning.

In order to define quality targets, identify consumers, ascertain customer wants, give measurement, design process features and controls, and enhance business strategies, Juran offers a set of universal procedures that can be applied in the fundamental managerial process. Setting quality goals, planning in "multifunctional" processes, creating data bases for quality planning, inspiring managers and the workforce, and implementing quality planning into companies are all given fresh attention by the author.

2.4 Audit Checklist for Drug Industries

The audit is a crucial component in assessing the development and market presence of any firm, but especially so in the pharmaceutical industry. The following are some of the items on the Important auditing criteria for quality assurance consider in order for an audit to be successful:

Pharmaceutical Quality Assurance Audit Checklist

2.5 Table of Contents

1.0 Quality Assurance Department
2.0 Validation
3.0 Documentation / Records
4.0 Labeling
5.0 Process Documents / Records
6.0 Standard Operating Procedures (Sops)
7.0 Vendor Qualification
8.0 Change Control Program

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 1, January 2023
Impact Factor: 6.252

9.0 Sample
10.0 Stability Studies
11.0 Drug Recalls
12.0 Annual Product Review
13.0 Equipment Logbooks
14.0 Audit / Complaints Internal Gmp Audits

1.0 Quality Assurance Department

- Is there a statement of the company's later quality policy?
- Does the business have a current organisational chart?
- Are the records from earlier audits still kept?
- Are parenteral goods created and developed in accordance with cGMP requirements and any other relevant codes, such as GLP and GCP, or excellent clinical and laboratory practises, respectively? (GCP).
- Are cGMP regulations adopted, and manufacturing and control activities are clearly established in writing?
- Is the job description explicit about responsibilities.
- Are components, intermediate goods, and other in-process checks, measurements, and validations subject to all necessary controls?
- Are final products truly handled and inspected in accordance with the documented procedures?

2.0 Validation

- A valid validation master plan, a valid cleaning master plan, valid validation protocols (for HVAC, purified water, WFI, process, cleaning, etc.), valid validation reports, and valid equipment qualification are all required. (IQ, OQ, PQ)
- Do validation studies follow pre-established methods (VMP) and validation planners?
- Were the production processes validated.
- Does the process control deal with an issue to ensure the identity, strength, quality, and purity of the product?
- All weighing and measuring tasks are completed by a trained and qualified individual, are watched formally signed by both parties on the record sheet by a second person.
- Are actions made to demonstrate a new master formula or preparation method's fitness for normal processing, as well as a process described, components listed, and equipment listed?
- Equipment and material validation.
- Have substantial modifications to the production process, such as any adjustments to the materials or equipment that might influence the quality of the final product, been validated?
- Are records for validation updated and preserved correctly.

3.0 Records and documentation

- Is documentation properly preserved in accordance with regulations and is it routinely examined and kept current?
- Is documentation kept in easily accessible, adequately divided areas?
- Is there a central repository for all documentation?
- Is the documentation precise, clear, and organised? Does it specify guidelines and practises for all types of materials, manufacturing processes, and quality control?
- Are all of the requirements, test methods, master formulas, packing guidelines, and standard operating procedures (SOPs) available, up to date, and being followed?
- Do the documents have traceability, an audit trail, and the existence of written evidence that will allow for an investigation?
- Does the record include information about receiving the sample, the processing equipment, the analytical testing, and the records of the lab equipment?

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 1, January 2023
Impact Factor: 6.252

4.0 Labeling

- Are tag affixed clearly and in accordance with the format established by the company to the containers, machinery, or buildings.
- Are status labels with different colours, such as "Quarantined," "Accepted," "Rejected," or "Cleaned," used?
- are all goods completed? branded according to specifications?

5.0 Process Records And Documents

- The above records and documents are available.
- Are all master copies of the documents available?
- Requirements for bulk , intermediate products records for process operation and batch processing.
- Batch packing records.
- Batch numbers;
- Record for packaging operation.
- A list of the batch's analysis results.
- Keep track of the releases of final products.
- A history of the issuance and retrieval of documents (BPR and Data Recording Formats)

6.0 Procedures for Standard Operating (SOPS)

- Are SOPs and related records of taken actions and decisions made found on the premises for the above.
- Assembling and validating equipment.
- Calibration and analytical tools
- Upkeep, sanitation, and cleaning
- Personnel issues, such as credentials, training, attire, and hygiene
- Environmental surveillance.
- Recalls of drugs; complaints; pest control

7.0 Vehicle Selection

- Do you have a list of authorized vendors that is up to date?
- Have the raw material (including active and inactive chemicals) and printed component suppliers been inspected and found to be satisfactory?

8.0 Change Control

- Is a SOP-backed format change control programme in place?, and is it being correctly followed? This includes initiating, reviewing, and approving changes to materials, sources, procedures, packaging for products, machinery, changes to batch sizes, etc.

9.0 Sample

- Is a sample of a lot or batch of the packaged or labelled drug kept on file by the company for at least a year following the labelled drug's expiration date?
- Does the business keep a sample of each lot or batch of raw materials, including both active and inactive components? • Are the retained samples correctly labelled and are records kept in accordance with SOP?

10.0 Stability Studies

- Does the company have a prospective and concurrent stability studies programme based on SOP and utilising the necessary equipment, such as climatic chambers that are continuously monitored for temperature and relative humidity (RH) and kept at 30°C/65% RH for ambient and 40°C/75% RH for stress conditions.
- Is the finished products' stability assessed and recorded before marketing?

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 1, January 2023
Impact Factor: 6.252

- Does the stability information support the product's specified shelf life? Any data deviations are examined, and the proper actions are performed if there are stability problems.

11.0 Drug Recalls

- Do you have a standard operating procedure in place for drug recalls?
- If the about question is affirmative, have there been any drug recalls in the last two years?

12.0 Annual Product Review

- Is there a procedure in place to review statistic data for all the items created during the year, such as trend analysis, reworks, rejects, and customer complaints.
- Include a price list and the names of the products you manufacture.
- Indicate where each product's raw materials are sourced.
- Do you export your goods? If yes, please specify where and what they are.

13.0 Equipment Logbooks

- The company maintains logbooks for all key and crucial equipment.
- Are the archive and logbook issuances appropriately documented?

14.0 Audit / Complaints

- GMP Internal Audits
- Do you have a successful internal GMP inspection programme that regularly checks all the manufacturing facilities, procedures, and QC labs?
- Is a process in place to resolve the errors, violations, or gaps found during internal GMP audits.
- The a department-by-department audit planner available?
- Verifies that any inconsistencies discovered during audits are in compliance.

III. CONCLUSION

An endeavour to establish the goal of a well-characterized method development endeavour is to create a dependable technique that can be demonstrated with a high degree of assurance to consistently produce data that meets stated criteria when employed within defined limitations. Analytical method development and evaluation can be done using QbD. All conceivable factors and all crucial analytical results are investigated to ascertain the relationships during method development. Important analytical factors include determined using a strategy that is similar to the process development methods mentioned in ICHQ8 and Q9. As techniques are created and as elements that could result in Method errors are identified and handled, the QbD process uses analytical scientists in active collaboration at both the development and operational labs.

Throughout the process, a corporate knowledge repository is needed to make sure that important data is recorded, So that lessons acquired can be applied to the specific approach under examination as well as to other similar methods being used to generate other products, it will be examined and expanded in the future. a similar repository will make it possible for the method to be continuously improved and changed during its lifecycle (in keeping with the ideas outlined in the draught ICH Q10).

Compared to ICH validation criteria (Q2(R1)), a QbD strategy for analytical methods that incorporates The standards for risk assessment, robustness testing, and ruggedness testing are much higher.

Additionally, it evaluates the method's variability in relation to One of the most important method characteristics to look for when deciding if a method is suitable for the task at hand is the specification limitations. task at hand. The strategy outlined here shows that, while offering some value, ICH Q2(R1) has to be significantly updated to take into consideration the QbD risk-based strategies outlined in this article.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 1, January 2023
Impact Factor: 6.252

REFERENCES

[1]. Woodcock J, The concept of pharmaceutical quality. American Pharmaceutical Review, 7(6), 2004, 10–15.
[2]. Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2006.
[3]. Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.
[4]. Lionberger RA, Lee LS, Lee L, Raw A ,Yu LX, Quality by design: Concepts for ANDAs, The AAPS Journal, 10, 2008,268–276.
[5]. FDA Guidance for Industry and Review Staff: Target Product Profile – A Strategic Development Process Tool (Draft Guidance).
[6]. Q8 (R1): Pharmaceutical Development, Revision 1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.
[7]. Callis JB, Illman DL, Kowalski BR, Process analytical chemistry. Analytical Chemistry, 59, 1987, 624A–637A.
[8]. Yu LX, Pharmaceutical quality by design: Product and process development, understanding, and control. Pharmaceutical Research, 25, 2008, 781–791.
[9]. Munson J, Gujral B, Stanfield CF, A review of process analytical technology (PAT) in the
[10]. U.S. pharmaceutical industry. Current Pharmaceutical Analysis, 2, 2006, 405–414.
[11]. Leuenberger H, Puchkov M, Krausbauer E, Betz G, Manufacturing pharmaceutical granules, Is the granulation end-point a myth, Powder Technology, 189, 2009, 141–148.
[12]. Miller CE, Chemometrics and NIR: A match made in heaven, Am. Pharm. Rev. Food and Drug Administration CDER,Guidance for industry, Q8 pharmaceutical development;2:41–48, 2006.
[13]. Nasr M. Risk-based CMC review paradigm, Advisory committee for pharmaceutical science meeting, 2004.
[14]. Food and Drug Administration CDER. Guidance for industry: Immediate release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1995.
[15]. Food and Drug Administration CDER. Guidance for industry: Modified release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997.
[16]. Food and Drug Administration CDER. Guidance for industry: Non sterile semisolid dosage forms scale-up and post approval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997.
[17]. Food and Drug Administration CDER. Guidance for industry: Changes to an approved NDA or ANDA, 2004.
[18]. Woodcock J, The concept of pharmaceutical quality. American Pharmaceutical Review, 2004, 1–3.
[19]. Food and Drug Administration, Office of Generic Drugs White Paper on Question-based Review:http://www.fda.gov/cder/ OGD/QbR.htm.
[20]. Food and Drug Administration, Guidance for industry, Q6A specifications for new drug substances and products: Chemical substances, 1999.
[21]. Nasr M, FDA's quality initiatives: An update, http://www.gmpcompliance.com/daten/download/ FDAs_Quality_Initiative.pdf, 2007.
[22]. Naresh Bhakar, Audit check list for quality assurance pharmaceuticals,2022.